Preclinical studies have demonstrated that targeted inactivation of NLRP3 inflammasome [such as indomethacin (Lu G. et al., 2017), INT-777 (Li B. et al., 2018), apocynin (Jin et al., 2019), T-614 (Hou et al., 2019), and MCC950 (Sendler et al., 2020)] alleviated AP progression and associated organ injury by suppressing inflammation and pancreatic acinar cell apoptosis. The gene discussed is NLRP3; the disease is alkaline phosphatase measurement.